
Current CMS pricing and breakdown for Nfct ds bv rna vag flu alg.
Non-Facility (Private Office) Rate
| Quarter | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|
| National Average Payment | $142.63 | $142.63 | $142.63 | $142.63 | $142.63 | $142.63 |
This item has a standard price nationwide. Your local rate will likely match the amount shown above.
Infectious disease, bacterial vaginosis, quantitative real-time amplification of rna markers for atopobium vaginae, gardnerella vaginalis, and lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis
CPT code 81513 (Infectious disease, bacterial vaginosis, quantitative real-time amplification of rna markers for atopobium vaginae, gardnerella vaginalis, and lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis) had a 2026 Medicare non-facility reimbursement rate of $142.63. This reflects a 0.00% change from the prior year.
The 2026 National Medicare reimbursement for 81513 is $142.63. This item is paid at a standard national rate, so local variation is typically minimal.
Description: Infectious disease, bacterial vaginosis, quantitative real-time amplification of rna markers for atopobium vaginae, gardnerella vaginalis, and lactobacillus spe.... Payment policies and coverage rules can still vary by setting and claim details, so confirm final guidance through CMS when needed.
| Quarter | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|
| National Average Payment | $142.63 | $142.63 | $142.63 | $142.63 | $142.63 | $142.63 |
| Quarter | Non-Facility Rate | Facility Rate | YoY % Change (Non-Fac) | YoY % Change (Fac) |
|---|---|---|---|---|
| 2026 Q3 | $142.63 | $142.63 | +0.00% | +0.00% |
| 2026 Q2 | $142.63 | $142.63 | +0.00% | +0.00% |
| 2026 Q1 | $142.63 | $142.63 | +0.00% | +0.00% |
| 2025 Q4 | $142.63 | $142.63 | — | — |
| 2025 Q3 | $142.63 | $142.63 | — | — |
| 2025 Q2 | $142.63 | $142.63 | — | — |
| 2025 Q1 | $142.63 | $142.63 | — | — |
| Component | Office (Non-Fac) | Facility (Hosp) |
|---|---|---|
| Work RVU | ||
| Practice Expense (PE) | ||
| Malpractice (MP) | ||
| Total RVUs | 0.00 | 0.00 |
Compare a payment against the Medicare benchmark for this code.
Medicare rates are used as a benchmark only. Actual payer contracts, modifiers, place of service, units, and billing rules may affect reimbursement. This tool is for educational and operational review purposes, not legal or billing advice.
National average reimbursement from major commercial payers based on CMS Transparency in Coverage machine-readable files.
| Modifier | Place of Service | Avg. Rate | vs Medicare | Percentile Range |
|---|---|---|---|---|
| NULL | Office (11) | $91.46 | -4.0% | $80 — $104 |
| NULL | Telehealth (02) | $88.20 | -7.4% | $76 — $102 |
| NULL | Facility (21) | $79.31 | -15.6% | $68 — $95 |
| NULL | Outpatient Hospital (22) | $84.92 | -10.2% | $71 — $99 |
| NULL | Home (12) | $96.14 | +1.0% | $84 — $113 |
Unlock commercial payer rates
See how BCBS, United, Aetna, and Cigna compare to Medicare for every code — included in MedFeeSchedule Pro.
Source: CMS Transparency in Coverage machine-readable files (MRFs). Commercial rates reflect payer-published negotiated amounts and may not reflect individual contracted rates.
Get notified when commercial payer rates launch
We're building payer rate comparison into MedFeeSchedule Pro. Enter your email to get early access.
Facility vs. non-facility pricing most commonly applies to physician services paid under the RVU-based Physician Fee Schedule. For 81513 (Clinical Laboratory Test), the payment methodology may not include both facility and non-facility rates.
Medicare reimbursement is determined by RVUs, geographic adjustments, and the annual conversion factor.
The 2026 National Average Medicare reimbursement rate for 81513 (Clinical Laboratory Test) is $142.63. This rate is effective as of January 1, 2026.
Infectious disease, bacterial vaginosis, quantitative real-time amplification of rna markers for atopobium vaginae, gardnerella vaginalis, and lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis
Facility vs. non-facility differences usually apply to RVU-based physician services. 81513 may not use both facility and non-facility pricing depending on its payment methodology.
Use MedFeeSchedule's Medicare Physician Fee Schedule Lookup Tool on the homepage to estimate your locality-adjusted reimbursement. Medicare payment can vary based on geographic adjustments (GPCI), place of service, and claim specifics.
Coverage depends on medical necessity, setting, and Medicare policy. Some codes may be bundled, contractor-priced, or restricted. Verify final coverage guidance through CMS or your local MAC when applicable.